Hypothyroidism
describes an ineffective thyroid gland that cannot make enough thyroid hormone.
This condition has no cure and can only be controlled by replacing the hormone
with a thyroid gland. The signs and symptoms of hypothyroidism are fatigue,
constipation, dry skin, puffy face, muscle weakness, muscle aches, tenderness,
stiffness, pain and stiffness. The major risk factors affecting by
hypothyroidism are autoimmune diseases, thyroid surgery, radiation therapy and
family history of thyroid disease.
According
to the study “Hypothyroidism
- Pipeline Review, H1 2018”, on a global scale the population with
iodine deficiency is increasing drastically. Iodine deficiency is predominant
compared to the large consumers of iodine and is particularly observed in
pregnant women and young children. Human body consists of minute amounts of
iodine in the thyroid gland and plays a major role in thyroid synthesis. Research reports state that over two billion
global populations have insufficient iodine intake. The introduction of various
remedies for the treatment of thyroid deficiency has encouraged the thyroid
therapeutics market over the past few years. It was observed that there is a
growing demand for the thyroid therapeutics in the developed and developing
regions worldwide. Therefore, thyroid therapeutic vendors are focusing more on
the emerging economies such as the Middle East, Africa, China, and India.
According to the research reports about 42 million people in India suffer from
hypothyroidism.
The
global thyroid therapeutics market is largely dominated by three leading
vendors; AbbVie, Pfizer, and Merck Sharp & Dohme. These vendors account for
a major part of the revenue shares. Abbvie invests in discovery, development,
manufacturing, and marketing the thyroid pharmaceutical products. Other leading
competitors in thyroid therapeutics market are Abbott, Allergan and RLC LABS.
Geographically, more American population account for hypothyroidism and opt for
thyroid gland disorder treatments. Globally, the population with hypothyroidism
is expected to increase the next few years due to modernisation and increase in
lifestyle diseases.
The
pipeline review guide for hypothyroidism provides comprehensive analysis on the
therapeutics that are under development, various drug analysis by stage of
development, drug target, mechanism of action (MoA), route of administration
(RoA) and molecule type involved in hypothyroidism therapeutics. It also covers
a descriptive pharmacological action of the therapeutics, complete research and
development history and latest news and press reports related to
hypothyroidism. The guide also provides details related to key players involved
in therapeutic development for Hypothyroidism, information related to emerging
players, enhances decision making capabilities and helps to create effective
counter strategies to gain competitive advantage. The hypothyroidism guide is
generated using information from various sources and dynamic tracking processes
that provide most recent developments are captured on a real time basis. This
trend will continue over the next few years so as to provide best treatment for
the increasing population with hypothyroidism.
To know more, click on the link below:
Related Reports:
Contact Us:
Ken
Research
Ankur
Gupta, Head Marketing & Communications
0124-4230204